Crescent Biopharma, Inc. (CBIO) Stock Analysis & Investment Frameworks
Crescent Biopharma, Inc. (CBIO) stock analysis on Invetso. Review Crescent Biopharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Crescent Biopharma, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Crescent Biopharma, Inc. Key Financial Metrics
- Market Cap: $481.76M
- Revenue: $10.84M
- ROE: -97.77%
- ROIC: -102.29%
- Dividend Yield: N/A
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.